Izokibep Ph2b/3 RCT PsA 340+ Primary endpoint ACR50 wk 16 IZO 160 mg Q2W 43% IZO 160 mg QW 40% PBO 15% Effect early a
Tweet Content
Izokibep Ph2b/3 RCT PsA 340+
Primary endpoint ACR50 wk 16
IZO 160 mg Q2W 43%
IZO 160 mg QW 40%
PBO 15%
Effect early as wk 4
PASI100
IZO Q2W 47%
IZO QW 51%
PBO 12%
Safety profile similar to IL-17i
@RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX
Show on Archive Page
On
Display in Search Results
On
PDQ
Off